Niagen Bioscience, Inc. (NAGE) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Niagen Bioscience, Inc.'s filing signal turned positive.

Niagen Bioscience, Inc. is a global bioscience company focused on promoting healthy aging through research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. The company's flagship product, Niagen(R), a form of vitamin B3, is available in food-grade and pharmaceutical-grade forms. Niagen(R) is sold directly to consumers as a dietary supplement under the Tru Niagen(R) brand and supplied as an ingredient to manufacturers and compounding pharmacies. The company also engages in pharmaceutical development of NAD+ precursors for rare diseases, though this segment currently generates no revenue. Niagen Bioscience operates globally, with significant distribution in over 100 countries through strategic partnerships.

Revenue is primarily driven by sales of Tru Niagen(R) consumer products and the sale of Niagen(R) as an ingredient to other manufacturers. The company also generates revenue from analytical reference standards and services, though this segment is being divested.